OFI Invest Asset Management Buys Shares of 31,265 Regeneron Pharmaceuticals, Inc. $REGN

OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 31,265 shares of the biopharmaceutical company’s stock, valued at approximately $24,133,000.

A number of other large investors have also made changes to their positions in the company. Jackson Square Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $407,000. Prime Capital Investment Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 12,783 shares of the biopharmaceutical company’s stock valued at $9,867,000 after buying an additional 309 shares in the last quarter. Greenleaf Trust increased its position in shares of Regeneron Pharmaceuticals by 4.8% in the 4th quarter. Greenleaf Trust now owns 1,472 shares of the biopharmaceutical company’s stock valued at $1,136,000 after buying an additional 67 shares in the last quarter. Asio Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $3,422,000. Finally, Clayton Financial Group LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $83,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, March 6th. They issued an “overweight” rating and a $923.00 price objective for the company. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Finally, Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $810.78.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $775.53 on Thursday. The stock has a 50-day moving average price of $766.90 and a two-hundred day moving average price of $717.58. The stock has a market cap of $81.99 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 2.02 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.07 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,774 shares of company stock worth $2,942,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.